REGENXBIO Q3 net loss $75.5M; cash $617M; RGX-314 BLA on track for 2024

REGENXBIO Inc.

2022-Q3 EPS reported -$5.11 revenue$81,379,000

Net loss of $75.5M ($1.75/share) vs $58.4M ($1.37/share) in Q3 2021; revenue $26.5M, down from $30.8M.
Cash, equivalents & marketable securities $617M as of Sept 30, 2022, down from $849.3M at Dec 31, 2021; runway into 2025.
RGX-314 subretinal pivotal trials (ATMOSPHERE, ASCENT) enrolling; BLA filing planned in 2024. AAVIATE and ALTITUDE trials expanded with new cohorts.
RGX-202 AFFINITY DUCHENNE Phase I/II trial on track for first patient dosing in H1 2023; RGX-121 CAMPSIITE pivotal trial enrolling for MPS II.
Zolgensma royalty revenue $25.2M in Q3 2022 vs $30.3M in Q3 2021; Novartis reported Q3 global sales of $319M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REGENXBIO Inc. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 3, 2022, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

REGENXBIO Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-021548

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.